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A novel Klebsiella pneumoniae carbapenemase (KPC) variant, KPC-55, produced by
a K. pneumoniae ST307 strain was characterized. K. pneumoniae strain BS407 was
recovered from an active surveillance rectal swab of a patient newly admitted to a
general hospital in Busan, South Korea. Carbapenemase production was confirmed by
the modified Hodge test, and the MICs of β-lactams were determined by the broth
microdilution method. The whole genome was sequenced. Cloning and expression
of the blaKPC-55 gene in Escherichia coli and MIC determination were performed.
The enzyme KPC-55 was used for kinetic assays against β-lactams and compared
with the KPC-2 enzyme. The new allele of the blaKPC gene had a T794A alteration
compared to the blaKPC-2 gene, resulting in the amino acid substitution Y264N in
the middle of the β9-sheet. Compared to the KPC-2-producing strain, the KPC-55-
producing strain exhibited a lower level of resistance to most β-lactam drugs tested,
however, the KPC-55 enzyme catalyzed aztreonam and meropenem at an increased
efficiency compared to the catalytic activity of KPC-2. KPC subtypes could have varied
phenotypes due to alterations in amino acid sequences, and such an unexpected
resistance phenotype emphasizes the importance of detailed characterizations for the
carbapenemase-producing Enterobacterales.
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INTRODUCTION
The β-lactam drugs are currently the most used class of antimicrobial agents; among them,
carbapenems are the most potent against Gram-positive and Gram-negative bacteria and have the
broadest spectrum of activity (Papp-Wallace et al., 2011). Klebsiella pneumoniae carbapenemase
(KPC) is one of the most worrisome carbapenem resistance determinants in clinical settings,
because it has broad spectrum of substrates including most β-lactams except cephamycins and it
appears to be produced by a broad range of bacterial hosts (Yigit et al., 2001; Nordmann et al.,
2011). The recent development regarding the inactivation of class A β-lactamases, including KPC,
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is the possibility to use avibactam in combination with
ceftazidime (van Duin and Bonomo, 2016). However, emerging
KPC subtypes resistant to avibactam is issuing (Gottig et al.,
2019). To date, a total of 54 allele types of KPC have been
deposited in the β-lactamase database1.
Klebsiella pneumoniae sequence type (ST) 307 was deposited
into the multilocus sequence typing database primarily in 2008,
and the ST307 strains are frequently resistant to late generation
cephalosporins through its production of CTX-M-15 extended-
spectrum β-lactamase (ESBL) (Wyres et al., 2019). In recent years,
the spectrum of resistance of the K. pneumoniae ST307 clone
was broadened to carbapenems by acquiring genes encoding
carbapenemases, such as KPC (Villa et al., 2017). The KPC-
producing K. pneumoniae clonal group (CG) has been changed
from CG235 to ST307 in recent years (Yoon et al., 2018b;
Cejas et al., 2019). In South Korea, most of the KPC-producing
Enterobacterales were K. pneumoniae ST11 belonging to CG235
until 2014 and from 2015, the KPC-producing clone was rapidly
exchanged to ST307 (Yoon et al., 2018b).
Here, we report a K. pneumoniae ST307 clinical strain
recovered from an active surveillance rectal swab specimen
against a new admission carrying an IncX3 plasmid, which
encodes a novel subtype KPC-55 with asparagine at position 264
instead of tyrosine as in the prototype KPC-2. The amino acid
substitution in the KPC-55 was responsible for the increased




This study was approved by the Institutional Review Board
of Inje University Busan Paik Hospital (No. 20-0036),
Busan, South Korea.
Clinical Strains Used in the Study
The K. pneumoniae strain BS407 was isolated from the CPE
screening step before hospitalization using rectal swab of a
patient in a university hospital in Busan, South Korea. The
patient information was obtained retrospectively. Antibiograms
were obtained by the disk diffusion test, and the carbapenemase-
producing phenotype of the strain was confirmed by the
modified Hodge test. For any comparison, the K. pneumoniae
lab-collection strain KP1559, which harbors the prototype
blaKPC-2 gene, was used.
Antimicrobial Susceptibility Testing
An antibiogram for K. pneumoniae strain BS407 was performed
by the disk diffusion test on Mueller-Hinton (MH) agar
(Becton Dickinson, Franklin lakes, NJ, United States) following
the CLSI guidelines (CLSI, 2019) with 15 antimicrobial
agents, i.e., piperacillin, amoxicillin/sulbactam, cefazolin,
cefotaxime, ceftazidime, cefepime, cefoxitin, aztreonam,
ertapenem, imipenem, meropenem, amikacin, gentamicin,
1http://www.bldb.eu/BLDB.php?prot=A#KPC, last updated in April 10, 2020
ciprofloxacin, and trimethoprim-sulfamethoxazole (Oxoid,
Basel, Switzerland). The MICs of tigecycline (Pfizer, New York
city, NY, United States), colistin (Sigma-Aldrich, St. Louis,
MO, United States), and the eight β-lactam drugs (Table 1)
were determined by the broth microdilution method using
MH broth (CLSI, 2019). For ceftazidime and imipenem, MICs
were determined with or without enzyme inhibitors, clavulanic
acid (Dong-A Pharmaceutical Co., Ltd., Seoul, South Korea),
and avibactam (BOC Sciences, Shirley, NY, United States).
Escherichia coli ATCC 25922 and Pseudomonas aeruginosa
ATCC 27853 were used for quality control of the tests.
Plasmid Transfer by Bacterial
Conjugation
For bacterial conjugation, the K. pneumoniae BS407 strain was
used as a donor, and a rifampicin-resistant mutant of E. coli
J53 was used as a recipient. Equal amounts of exponential
cultures of the donor, K. pneumoniae BS407, and recipient
isolates were mixed, incubated in MH broth for 12 h, and
spread on MH agar containing rifampicin (30 µg/ml), sodium
azide (100 µg/ml), and imipenem (0.5 µg/ml). Any colony
at the selective plate was tested by disk diffusion test and
confirmed by PCR.
DNA Manipulation and Cloning
The blaKPC-2 and blaKPC-55 genes were amplified
from the total DNA of K. pneumoniae KP1559
and BS407, respectively, using KPC_F (5′-
AGGAGGTAAATAATGTCACTGTATCGC CGTCTAGTT-3′)
and KPC_R (5′-TTACTGCCCGTTGACGCCCAA-3′) using
Phusion R© High-Fidelity DNA polymerase (Thermo Fisher
Scientific, Waltham, MA, United States). Each PCR product
was purified and cloned into the pCR-Blunt vector (Invitrogen,
Thermo Fisher Scientific). The recombinant plasmids were
transformed into chemically competent E. coli One ShotTM
TOP10 (Invitrogen, Thermo Fisher Scientific) and selected
on MH agar containing kanamycin 50 µg/ml and ampicillin
50 µg/ml. Nucleic acid sequences and the direction of each insert
were verified by Sanger sequencing using the universal M13
primers of both directions.
Analysis of the Entire Genome
The whole genome of K. pneumoniae strain BS407 was sequenced
using both Illumina and Nanopore technologies. DNA was
extracted with the GenEluteTM Bacterial Genomic DNA Kit
(Sigma), and libraries were prepared for Illumina using the
Swift 2S Turbo DNA Library Kit (Swift Biosciences, Ann Arbor,
MI, United States) and Swift 2S Turbo Combinatorial Dual
Indexing Primer Kit (Swift Biosciences) and for Nanopore
using the Ligation Sequencing Kit (Oxford Nanopore, Oxford,
United Kingdom). Reads were assembled using Spades (version
3.11.1), and the complete sequences were annotated using
prokka 1.13.72. Identification of resistance determinants and
2https://github.com/tseemann/prokka
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TABLE 1 | MICs of β-lactams.
MICs (µg/ml)
K. pneumoniae E. coil
BS407 KP1559 TOP10 TOP10 TOP10
β-Lactamsa blaKPC−55 blaKPC-2 blaKPC−55 blaKPC-2
Ampicillin >32 >32 >32 >32 4
Aztreonam 16 >32 16 >32 0.125
Cefotaxime 16 >32 1 8 <0.0625
Ceftazidime 16 >32 8 32 0.25
Ceftazidime + CAb 16 4 0.5 0.25 0.25
Ceftazidime + ABc 0.125 2 0.5 0.25 0.25
Cefoxitin 32 >32 2 >32 2
Cefepime 8 >32 1 8 <0.0625
Imipenem 1 8 0.5 1 0.125
Imipenem + CA 0.5 <0.0625 0.25 0.125 0.125
Imipenem + AB <0.0625 <0.0625 0.5 0.25 0.25
Meropenem 2 16 0.25 1 <0.0625
aAmpicillin (Sigma-Aldrich), aztreonam (Daehan New Pharm Co., Ltd., Gyeonggi-do, South Korea), cefotaxime (Aju Pharm Co., Ltd., Seoul, South Korea), ceftazidime
(Sigma-Aldrich), cefoxitin (JW pharmaceutical, Co., Ltd., Seoul, South Korea), cefepime (Boryeong Pharmaceutical Co., Ltd., Seoul, South Korea), imipenem (MSD, Co.,
Inc., Kenilworth, NJ, United States), and meropenem (Sigma-Aldrich). bCA, clavulanic acid (Dong-A Pharmaceutical Co., Ltd., Seoul, South Korea). cAB, avibactam (BOC
Sciences, Shirley, NY, United States).
FIGURE 1 | The KPC-55 protein in comparison with the prototype KPC-2. Top, the active site and binding site of the KPC enzyme corresponding to the 2OV5
protein database structure (Ke et al., 2007). Two hinge regions, the  loop and the substrate binding site, are indicated in the amino acid sequences in orange,
green, and red, respectively. Middle, the sequence of KPC-55 compared with that of KPC-2 is presented. The Y264N alteration is illustrated with a red dot. Bottom,
secondary structure of KPC-2 indicating β-sheets in light yellow and α-helices in dark red (Ke et al., 2007).
plasmid incompatibility typing were assessed using ResFinder3
and plasmid finder4, respectively.
Purification of the KPC Enzymes
Klebsiella pneumoniae BS407 and KP1559 cells were harvested by
centrifugation, and the bacterial cells were resuspended in 15 mM
sodium phosphate buffer (pH 7.0). The cells were disrupted by
sonication, and the debris was eliminated by centrifugation at
15,000 × g for 30 min at 4◦C. The crude extract was then passed
through a 0.45-µm Millipore membrane filter (MilliporeSigma,
Burlington, MA, United States) and loaded on a 10 ml Poly-
Prep column (Bio-Rad, Hercules, CA, United States) filled with
aminophenylboronic acid agarose (Sigma) at a flow rate of
1 ml/min (Bauvois et al., 2005). Then, the enzyme was eluted by
a linear borate gradient (0 to 0.5 M) in 20 mM triethanolamine-
HCl and 0.5 M NaCl (pH 7.0) over 5 ( column volumes at a flow
rate of 1 ml/min. The fractions exhibiting (-lactamase activity
were collected, and their purity was estimated by electrophoresis
on a sodium dodecyl sulfate-polyacrylamide gel stained with




Kinetic measurements were carried out using KPC enzymes
in 50 mM morpholinepropanesulfonic acid (pH 7.0), 50 mM
NaCl, and 100 mM sodium phosphate (pH 7.0) at 30◦C
(Bauvois et al., 2005). A Lambda 25 UV–visible (UV–Vis)
spectrophotometer (PerkinElmer, Waltham, MA, United States)
was used to determine the rates of hydrolysis. Various
concentrations of the drugs were preincubated with the enzyme
at 30◦C to determine the kinetic parameters. All the values were
determined in triplicate.
Statistical Analysis
All kinetic results are presented as averages± standard deviations
from a minimum of three replicates.
Accession Number
The genome sequence of the plasmid pBS407-3 was deposited
in the United States National Center for Biotechnology
Information (NCBI) database under the GenBank accession
number MT028409, and the allele number of the blaKPC-55 gene
was designated under the curation by the Bacterial Antimicrobial
Resistance Reference Gene Database of the NCBI.
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RESULTS
Case Description
The K. pneumoniae BS407 strain was recovered from a rectal
swab of >80-year-old patient admitted for hospitalization at
Inje University Busan Paik Hospital, Busan, South Korea. The
patient was subjected to active surveillance for carbapenemase-
producing Enterobacterales (CPE) at the stage of admission.
The K. pneumoniae BS407 strain was resistant to
ciprofloxacin and all β-lactam drugs tested, i.e., penicillins
(ampicillin, piperacillin, and ampicillin-sulbactam with
an inhibition zone diameter of 6 mm), narrow-spectrum
(cefazoline, 6 mm) and extended-spectrum cephalosporins
(cefotaxime, 18 mm; ceftazidime, 14 mm; and cefepime,
16 mm), cephamycin (cefoxitin, 14 mm), monobactam
(aztreonam, 8 mm), and carbapenems (ertapenem, 15 mm;
imipenem, 19 mm; and meropenem, 17 mm), but susceptible
to aminoglycosides (amikacin, 22 mm; gentamicin,
24 mm), tigecycline (MIC, 2 µg/ml), and colistin (MIC,
2 µg/ml), and the strain showed intermediate resistance to
trimethoprim-sulfamethoxazole (15 mm).
Identification of a Novel KPC Subtype
Phenotypic verification using the modified Hodge test indicated
that the BS407 strain was a carbapenemase producer, and PCR
and direct sequencing confirmed that the strain harbored the
blaKPC gene, whose allele had never been deposited in the
GenBank database. The novel gene encoding the new KPC
variant had one nucleic acid alteration of T794A, resulting
in asparagine instead of tyrosine at position 264 of the
prototype KPC-2 (Figure 1). The altered amino acid was
located in the middle of the β9-sheet, apart from the active
site. Variable subtypes of KPC enzymes had one (KPC-52) to
15 aa (KPC-44) insertions between β9 and α12, 250 aa to
273 aa (Figure 2); however, the same substitution had not been
identified previously.
Genome Analysis of the K. pneumoniae
BS407 Strain
The sequences of the whole genome of K. pneumoniae BS407
indicated that the strain belonged to ST307 and had the
capsular type wzi110. The genome was composed of a 5,477,837-
bp chromosome and four circularized plasmids of 136,158,
100,435, 50,505, and 3,551 bp in size. The intrinsic blaSHV
gene encoded SHV-28, an ESBL (Kim et al., 2006). In addition,
the resistance determinants to fosfomycin, the fosA gene, was
acquired in the chromosome, and the resistance-associated
nucleic acid mutations was not observed in the chromosome,
i.e., those at the quinolone resistance determining region or at
the global regulator. The plasmids carried one to six resistance
determinants, except the 3,551-bp cryptic plasmid: the aac(6′)-
Ibcr and qnrB1 genes for quinolone resistance, the tet(A) gene
for tetracycline resistance, the catB3 gene for chloramphenicol
resistance, the dfrA14 gene for trimethoprim resistance, and
the blaOXA-1 gene for β-lactam resistance in the IncFIB-type
136,158-bp plasmid; the qnrS1 gene for quinolone resistance
in the IncFIB/FII-type 100,435-bp plasmid; and the blaKPC−55
and blaSHV−182 genes for β-lactam resistance in the IncX3-type
50,505-bp plasmid.
The blaKPC−55 gene was located on a truncated Tn4401a
transposon composed of 1ISKpn7-blaKPC−55-ISKpn6
(Figure 3). The genes for transposase and resolvase composing
the 3′ half of the transposon were absent together with the gene
for transposase comprising the ISKpn7 element. The intergenic
region between the ISKpn7 element and the blaKPC−55 gene was
99 bp shorter than the longest isotype Tn4401b, indicating that
FIGURE 2 | The variable region of the KPC subtypes between aa 250 and aa
278. The secondary structure of KPC-2 is indicated at the top with β-sheets in
light yellow and alpha-helices in dark red. The amino acid sequence of
KPC-55 is in the yellow open box. The sequences of the KPC subtypes were
obtained from the Bacterial Antimicrobial Resistance Reference Gene
Database ver. 2020-01-22.1 (BioProject accession, PRJNA313047; last
accessed on 2020.2.5.).
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FIGURE 3 | The 50,505-bp IncX3 plasmid carrying the blaKPC-55 gene in K. pneumoniae BS904. The open arrow indicates open reading frames, and the function of
the protein encoded by the gene is represented by color: orange, replication and assembly; yellow, transposase; red, antimicrobial resistance; black, conjugation;
white, others. The unlabeled ORF encodes a hypothetical protein. The green box indicates the truncated Tn4401. The complete structure of Tn4401 is indicated at
the top.
TABLE 2 | Kinetic parameters of the β-lactamases KPC-55 and KPC-2.
Hydrolysis activitya
KPC-55 KPC-2
Substrate kcat (s−1) Km (µM) kcat/Km (s−1 µM−1) kcat (s−1) Km (µM) kcat/Km (s−1 µM−1)
Ampicillin 0.06 ± 0.05 0.03 ± 0.01 1.89 ± 1.81 5.31 ± 2.8 1.03 ± 0.38 4.98 ± 0.77
Aztreonam 27.89 ± 5.20 1.50 ± 0.31 18.58 ± 0.36 2.56 ± 3.23 1.17 ± 1.29 1.85 ± 0.50
Ceftazidime 0.20 ± 0.33 0.40 ± 0.11 0.45 ± 0.74 0.02 ± 0.003 0.28 ± 0.09 0.07 ± 0.02
Imipenem 1.99 ± 0.64 0.13 ± 0.002 15.14 ± 4.61 0.41 ± 0.30 0.03 ± 0.02 37.48 ± 47.21
Meropenem 1.34 ± 0.05 0.02 ± 0.01 80.49 ± 35.18 0.09 ± 0.03 0.02 ± 0.02 5.19 ± 2.93
aData are the means of three independent determinations.
it was a Tn4401a element. The IncX3-type plasmid carrying the
blaKPC−55 gene bracketed by the truncated Tn4401a element
furnished the Type IV secretion system, contributing to conjugal
DNA transfer (Figure 3). However, the transfer efficiency of
the IncX3 plasmid carrying the blaKPC−55 gene was less than
the detection limit, <10−9, which means that the plasmid was
hardly transferable.
Substrate Spectrum and Inhibitory
Characteristics of KPC-55
To evaluate the spectrum of resistance, the corresponding
blaKPC−55 gene was cloned into the pCR-Blunt vector and
introduced into the E. coli OneShot TOP10 strain. When the
gene was expressed in the E. coli host, the gene conferred
reduced susceptibility to most β-lactams; however, the resulting
MICs were consistently lower than the MICs with the blaKPC-2
gene (Table 1). As the blaKPC-2 transformant, the blaKPC−55
gene transformant presented diminished MICs of imipenem
and ceftazidime by adding enzyme inhibitors, either clavulanic
acid or avibactam.
Kinetic data using the enzyme showed that compared to
that KPC-2, the hydrolytic activity of KPC-55 was lower for
ampicillin and higher for aztreonam and meropenem (Table 2).
The diminished catalytic efficiency for ampicillin was a result of
the combination of the decreased turnover number and increased
affinity. The higher catalytic efficiency of KPC-55 to aztreonam
and meropenem was associated mostly with the improved
turnover efficiency, not the affinity. It could be speculated that
the alteration of Y264N could allow the enzyme to catalyze more
meropenem and aztreonam but not ampicillin and increased the
affinity of the enzyme to ampicillin. The catalytic efficiency of
KPC-55 against imipenem and ceftazidime was indifferent from
that of KPC-2, and KPC-55 presented similar levels of inhibition
by clavulanic acid and avibactam to KPC-2.
DISCUSSION
The emergence of plasmid-mediated KPC enzymes in 1996 (Yigit
et al., 2001) was a prelude of a global epidemic of CPE. The
prototype KPC-2 is able to hydrolyze most β-lactams, with great
efficiency for penicillins, cephalosporins and carbapenems and
diminished efficiency for cephamycins and ceftazidime (Yigit
et al., 2001). The identification of a number of KPC-2 variants
possessing amino acid substitutions presented a varied spectrum
of substrates for hydrolysis (Mehta et al., 2015). In particular, any
alteration in the KPC active site, which is encompassed by the
-loop of R164 to D179, the hinge between helices α3 and α4 and
another hinge region between helices α10 and α11, could affect
the hydrolysis activity of the KPC enzyme (Galdadas et al., 2018).
KPC-4 possessing the P103R substitution at the α3-α4 hinge
has higher ceftazidime-hydrolytic activity but lower carbapenem-
hydrolytic activity compared to KPC-2 (Wolter et al., 2009),
and KPC-3 possessing the L169P alteration at the -loop
confers resistance to the bacterial hosts against the enzyme
inhibitor avibactam, which inactivates KPC-2 (Hemarajata and
Humphries, 2019). Not only the alterations located at the three
loops but also the substitutions occurring at the other parts of the
enzyme, such as the insertion of PNK between D269 and D270
in KPC-41, are responsible for reduced carbapenem-hydrolyzing
activity and increased inhibition by avibactam (Mueller et al.,
2019). All these examples highlight the importance of exploring
new variants of the enzyme and characterizing them for their
altered hydrolyzing activity.
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In this study, a new allele of the KPC-2 variant with the
Y264N alteration was characterized. The results indicate that
the Y264N alteration was responsible for the reduced MICs
of aztreonam, extended-spectrum cephalosporins, cefoxitin, and
cefepime, and carbapenems in E. coli transformants presenting
a good correspondence with the hydrolyzing activity test results
using the enzyme. Interestingly, the alteration led to higher
meropenem-hydrolyzing activity, even though the substitution
was distantly located from the -loop and any other hinges
composing the active site. The β9-sheet and the following hinge
to the α12-helix is a variable region; six of the 46 deposited
KPC alleles have one- to 15-amino acid insertions in this region.
Among those, only one allele, KPC-52, had an altered β9-sheet
by insertion of valine between A259 and V260 (Figure 2);
however, unfortunately, kinetic assay data for KPC-52 for proper
comparison are unavailable.
The IncX3-type plasmid harboring the blaKPC-55 gene
resembled the 69,409-bp plasmid pECSEV_01 in E. coli EcU443
recovered in 2014 from Seoul, South Korea (Jeong et al.,
2018). They shared 99.9% nucleic acid identity showing 89%
of query coverage. Of note, the reverse presented 100% of
coverage including the duplicated conjugative elements in the
pECSEV_01. The pECSEV_01 plasmid has been identified to
harbor the blaKPC-2 gene carried by a truncated Tn4401a
1ISKpn7-blaKPC-55-ISKpn6 as the truncated Tn4401a harboring
the blaKPC-55 gene.
The strain carrying the blaKPC−55 gene belonged to ST307,
which is a worldwide K. pneumoniae clone resistant to extended-
spectrum cephalosporins and carbapenems through varied
acquired resistance determinants (Villa et al., 2017). The ST307
clone possessing the blaKPC-2 gene mobilized by the Tn4401a
transposon has been predominant in South Korea (Kim et al.,
2017; Yoon et al., 2018a), and it could be speculated that a point
mutation occurred on the coding sequences of the blaKPC-2 gene,
resulting in the BS407 strain. The K. pneumoniae ST307 clone
is commonly resistant to multiple antimicrobial drugs but rarely
harbors virulence factors (Kim et al., 2019). Because of its traits,
the clone is linked with healthcare-associated infections (Kim
et al., 2019) and associated with higher mortality than the other
clones (Villa et al., 2017). Moreover, mortality in patients with
infections caused by KPC-producing K. pneumoniae is high, up
to 41.0% (Ramos-Castaneda et al., 2018), and even the carriage
of KPC-producing K. pneumoniae is a risk factor for mortality
in patients with diabetic foot disease (Tascini et al., 2015). Novel
variants of the KPC enzyme have been reported in isolates
identified not only from infection sites but also from active
surveillance (Mueller et al., 2019). Therefore, following up both
the dominant clonal lineage of KPC producers and the subtype
of KPCs produced by Enterobacterales should be actively carried
out both for infection-causative CPE and for carriages.
In conclusion, we reported here K. pneumoniae ST307
strain producing KPC-55, KPC-2Y264N, conferring reduced
susceptibility to carbapenems. The alteration is located out of
the known active site of the KPC enzyme, and a detailed kinetic
assay revealed that the alteration led to higher meropenem-
hydrolytic activity than the prototype KPC-2. KPC subtypes
could have varied phenotypes by alterations, and the CPEs
producing such an allele conferring low-level resistance could
be missed in routine screening even though their catalytic
activity toward some carbapenems can be improved. Thus,
paying close attention to CPE screening is needed, and detailed
characterization should be carried out.
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